Sanofi
USE OF ANTI-CEACAM5 IMMUNOCONJUGATES FOR TREATING LUNG CANCER
Last updated:
Abstract:
The present disclosure provides methods of treating high CEACAM5 expressing cancers including lung cancers such NSQ NSCLC using immunoconjugates comprising an antibody that specifically binds human CEACAM5.
Status:
Application
Type:
Utility
Filling date:
6 Feb 2020
Issue date:
17 Mar 2022